23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Denmark compensates patients after vision loss linked to Novo drugs

An increasing number of patients in Denmark are being granted compensation after developing the serious eye condition NAION following treatment with Novo Nordisk’s drugs Wegovy and Ozempic.
Advertisement

NAION (non-arteritic anterior ischemic optic neuropathy) is a rare condition caused by reduced blood flow to the front part of the optic nerve. It can cause visual field defects and sudden vision loss, which may be permanent.

Novo Nordisk maintains that no causal relationship between the drugs and the condition has been established and has not accepted any legal liability. Nevertheless, the Danish Patient Compensation Association has so far approved compensation in 31 cases, Bloomberg News reports.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.078|